[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-359279-105":59,"doc-detail-359279-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","mast-cell-derived-nerve-growth-factor-drives-ilc2-pro-tumoral-functions-in-bladder-cancer","Mast-cell derived nerve growth factor drives ILC2 pro-tumoral functions in bladder cancer","","Innate lymphoid cells type 2 (ILC2s) can promote tumor growth, but the upstream triggers in bladder cancer remain unclear. This study identifies nerve growth factor (NGF) as a driver of ILC2 pro-tumoral functions. Tumor NGF-producing mast cells accumulate in the microenvironment, activate ILC2s via the NGF receptor TrkA, and induce type-2 cytokine secretion and regulatory T cells (Tregs), fostering tumor growth. In patients, NGF levels inversely correlate with survival in ILC2-rich tumors. In vivo, a selective TrkA inhibitor improves survival in orthotopic tumor-bearing mice and sensitizes to immune checkpoint blockade.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/mast-cell-derived-nerve-growth-factor-drives-ilc2-pro-tumoral-functions-in-bladder-cancer/359279/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/mast-cell-derived-nerve-growth-factor-drives-ilc2-pro-tumoral-functions-in-bladder-cancer/359279.png","ImageObject",300,407,{"name":92,"@type":93},"Jake","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What role do ILC2s play in bladder cancer according to the study?","Question",{"text":112,"@type":113},"ILC2s can exhibit pro-tumoral functions in bladder cancer by promoting an immunosuppressive environment and increasing the MDSC/T-cell ratio.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does NGF influence ILC2 activity in the tumor microenvironment?",{"text":117,"@type":113},"NGF-producing mast cells accumulate in tumors and activate ILC2s through the NGF receptor TrkA, leading ILC2s to secrete type-2 cytokines and promote regulatory T cells (Tregs).",{"name":119,"@type":110,"acceptedAnswer":120},"What therapeutic implication is suggested by TrkA inhibition?",{"text":121,"@type":113},"Selective inhibition of TrkA improves survival in orthotopic tumor-bearing female mice and sensitizes tumors to immune checkpoint blockade, suggesting a potential targetable strategy.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},359279,1790656782,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962084928904,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Article [https://doi.org/10.1038/s41467-026-69841-y](https://doi.org/10.1038/s41467-026-69841-y)  \nMast-cell derived nerve growth factor drives ILC2pro-tumoral functions in bladder cancer  \nReceived: 19 February 2024  \n\n| Accepted: 11 February 2026 |\n| --- |\n| |\n| Check for updates |\n\nMaryline Falquet 1,2,3,4,5, Hajar El Ahanidi1,2,3,4,5,23,  \nAlejandra Gomez-Cadena1,2,3,4,5,23, Ziyang Su1,2,3,4,5, Anthony Cornu 1,2,3,4,5,22, Tania Wyss 6, Burak Kizil1,3,4,5, Robert Pick 1,3,4,5, Katayoun Falamaki7, Pratyaksha Wirapati 1, Benedetta Fiordi1,2,3,4,5, Isis Senoner1,  \nDaniela Claudia Maresca 8, Neil Kallal 1,3,5, Danaé Guedj 1,2,3,4,5,  \nMario Kreutzfeldt 1,9, Jean-Christophe Tille9, Marine M. Leblond2,10, Katarzyna Michaud11, Silvia Pesce12,13, Simona Candiani13,14, Korneliusz Golebski15, Julien Dagher16, Melinda Charrier17, Caroline Pressacco Brossier18,  \nElisabeth Grobet-Jeandin18, Romina Marone 19,20, Stéphanie Hugues1,3,5, Lukas T. Jeker 19,20, Grégory Verdeil 2,10, Doron Merkler 1,3,5,  \nEmanuela Marcenaro 12,13, Christoph Scheiermann 1,3,4,5,  \nMohammed Attaleb21, Daniel Benamran18, Petros Tsantoulis 5,6,17,  \nGiuseppe Ercolano 8,24, Sara Trabanelli 1,2,3,4,5,24 &  \nCamilla Jandus 1,2,3,4,5,24   \nInnate lymphoid cells type 2 (ILC2s) are key regulators of tissue homeostasis and inﬂammation. In cancer, ILC2s can exhibit pro-tumoral functions by increasing the myeloid derived suppressor cells (MDSC)/T-cell ratio. Nevertheless, the upstream ILC2 triggers remain poorly deﬁned. Here, we identify nerve growth factor (NGF) as the driver of ILC2 pro-tumoral functions inpatients with bladder cancer. We show that ILC2s express the NGF receptor TrkA and respond to NGF by secreting type-2 cytokines. In the tumor microenvironment, NGF-producing mast cells accumulate and activate ILC2s to induce regulatory T cells (Tregs), ultimately fostering tumor growth. Inpatients, NGF levels inversely correlate with survival in ILC2-rich tumors, underscoring the clinical signiﬁcance of this axis. In vivo administration of a selective TrkA inhibitor improves survival in orthotopic tumor-bearing female mice and sensitizes them to immune checkpoint blockade (ICB). Overall, we identify NGF as an ILC2 activator that shapes pro-tumoral ILC2 functions. The blockade of TrkA+ ILC2s might represent a targetable strategy to improve survival, particularly in ICB-resistant patients.  \nBladder cancer (BC) is the 10th most diagnosed cancer, characterized by a poor response to conventional treatment and high relapse rate1. Up to 40% of patients with non-muscle invasive bladder cancer (NMIBC) fail to respond to intravesical bacillus Calmette-Guérin (BCG) therapy2, and relapse or progress to the muscle invasive (MIBC) or metastatic state. Despite encouraging clinical activity in multiple  \nclinical settings, anti-PD-1/PD-L1 therapies only produce durable beneﬁt in a minority of patients with BC3. There is thus an urgent need for the identiﬁcation of new therapies for BC.  \nBC is distinguished by a predominant immunosuppressive immune cell inﬁltrate unable to mount an adequate response to immunotherapies4. The BC immunosuppressive microenvironment is  \nA full list of afﬁliations appears at the end of the paper. [e-mail:](e-mail: Camilla.jandus@unige.ch)[ Camilla.jandus@unige.ch](e-mail: Camilla.jandus@unige.ch)  \nsustained by different immune cells such as regulatory T cells (Tregs), tumor associated macrophages5 and type 2 innate lymphoid cells (ILC2s) that, via IL-13 secretion, modulate the T cell/monocytic myeloid-derived suppressor cell (M-MDSC) ratio in favor of immune evasion6.  \nILC2s are a subset of innate lymphoid cells (ILCs) that release IL-5 and IL-13, driving a type 2 immune response7–9, which is involved in tissue homeostasis, infection, inﬂammation and cancer10,11. The ILC family represents the innate counterpart of helper CD4 T cells, sharing similar transcription factors and specialized cytokine secretion10. As tissue resident cells, ILCs respond qui","cbCaiphdXjMQZLqs","https://ap.wps.com/l/cbCaiphdXjMQZLqs","pdf",2839548,18,"English","# Background\n## Clinical challenges in bladder cancer\n## Immunosuppressive tumor microenvironment and ILC2 biology\n## Neuronal-derived factors and NGF rationale\n# Study aims and key findings\n## NGF as the upstream trigger for ILC2 pro-tumoral functions","[{\"question\":\"What role do ILC2s play in bladder cancer according to the study?\",\"answer\":\"ILC2s can exhibit pro-tumoral functions in bladder cancer by promoting an immunosuppressive environment and increasing the MDSC/T-cell ratio.\"},{\"question\":\"How does NGF influence ILC2 activity in the tumor microenvironment?\",\"answer\":\"NGF-producing mast cells accumulate in tumors and activate ILC2s through the NGF receptor TrkA, leading ILC2s to secrete type-2 cytokines and promote regulatory T cells (Tregs).\"},{\"question\":\"What therapeutic implication is suggested by TrkA inhibition?\",\"answer\":\"Selective inhibition of TrkA improves survival in orthotopic tumor-bearing female mice and sensitizes tumors to immune checkpoint blockade, suggesting a potential targetable strategy.\"}]","Mast-cell derived nerve growth factor drives ILC2 pro-tumoral functions in bladder cancer | PDF",1790136588,45,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4bf5b1ec319763fbd8707593006a655b.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/08d34c2df3afc74a01a7ec1187395b54.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/add1cfc4d46c82440be7efbf6194bc82.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/98f78946176b2fea8923bd73ae024e3a.webp",980,1301]